drugset / Trial / NCT04363034
Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program
Summary
This is an expanded access treatment protocol to treat up to 100 patients with severe or life-threatening, laboratory confirmed COVID-19 with COVID-19 convalescent plasma.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Convalescent Plasma | Protein / enzyme biologic | 200 ml | — |
| Subject | Convalescent Plasma | Protein / enzyme biologic | 400 ml | — |